Addendum
Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07
Report documents
-
Addendum
Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07
Dossier assessment
Indication:
Adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
Result of dossier assessment:
- Patients with visceral disease: indication of minor added benefit
- Patients without visceral disease: indication of major added benefit
Additional information
Federal Joint Committee (G-BA)
2023-07-20 A G-BA decision was published.
Project details
- Project no.
- A23-52
- Commission
- Commission awarded on 06.06.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed